GlucoCEST MRI in Oncology
NCT03212157 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15
Last updated 2021-09-29
Summary
The roles of imaging in cancer may be divided into that of diagnosis and tumour detection, staging and assessment of response to treatment. Standard radiological techniques include ultrasound, Computed Tomography (CT), Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET). A combination of imaging techniques is often necessary to differentiate between cancerous and normal tissue. Traditional imaging techniques identify cancers by their gross appearance and structural/ cellular characteristics, whilst PET do so by tracking glucose metabolism. PET owes its specificity to the high rate of glucose metabolism seen in most cancers. However it is not used routinely due to a lack of availability and high costs. In addition, PET is often used in combination with CT, which imparts a significant diagnostic radiation dose. This can increase an individual's risk of cancer, especially with childhood or early adult exposure. In contrast, MRI is more readily available and does not involve radiation. However its ability to detect cancer by tracking glucose metabolism has not been widely explored. Our group has recently developed a novel MRI technique called Gluco-CEST that can image glucose delivery, uptake and metabolism in cancer, therefore potentially allowing a radiation-free, one-stop imaging service that can be adapted to current generation of MRI scanners. This study aims to optimise the GlucoCEST technique, after which it will be rigorously tested and compared to standard imaging parameters and clinical or pathological reference standards to evaluate its diagnostic and predictive power across a number of cancer populations.
Conditions
Interventions
- OTHER
-
Glucose infusion
Infusion of 20% dextrose (drug) and using this as an imaging tracer in detecting and staging tumours.
- DIAGNOSTIC_TEST
-
Magnetic Resonance Imaging (MRI)
MRI scanners (device) use strong magnetic fields, radio waves, and field gradients to generate images of the organs in the body. Specifically using the MRI scanner with the infusion of dextrose in detecting and staging tumours.
- DIAGNOSTIC_TEST
-
FDG PET
FDG is a sugar (glucose) labelled with a small amount of radioactivity which goes to parts of the body that use glucose for energy. PET/CT images are acquired on a single scanner. An FDG PET scan can be used to assess the presence, location and severity of cancers.
Sponsors & Collaborators
- collaborator OTHER
-
University College, London
lead OTHER
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- BASIC_SCIENCE
- Masking
- NONE
- Model
- SEQUENTIAL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2017-01-06
- Primary Completion
- 2019-09-01
- Completion
- 2019-10-08
Countries
- United Kingdom
Study Locations
More Related Trials
-
Comparison Between FDG-PET and MRI for the Assessment of Response to Intensive Chemotherapy in Multiple Myeloma Patients.
NCT00200668 ·Status: TERMINATED ·Phase: NA
-
Early Therapy Response Monitoring in Melanoma Patients Using PET/MRI
NCT03132090 ·Status: UNKNOWN ·Phase: NA
-
Determine Tumor Response Using Fluorodeoxyglucose (FDG)- Positron Emission Tomography (PET)/Computed Tomography (CT) Before and After Cetuximab in Patients With Head and Neck Cancer
NCT00671437 ·Status: COMPLETED ·Phase: PHASE2
-
Renal Tumour Imaging Using MRI
NCT07173140 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Diagnostic Accuracy of MRI, DWI MRI, FDG-PET/CT and FEC PET/CT in the Detection of Lymph Node Metastases in Surgically Staged Endometrial and Cervical Carcinoma
NCT01836484 ·Status: COMPLETED
-
Functional Imaging of Tumor and Normal Tissue
NCT00933114 ·Status: TERMINATED
-
Integrated PET/MR Imaging With Amino Acid Radiotracers in the Evaluation of Brain Neoplasms: Assessing Diagnostic Accuracy and Therapeutic Response
NCT07211360 ·Status: NOT_YET_RECRUITING
-
PET/CT Whole-body Dynamic Acquisition at FDG to Metastatic Melanoma Under Immunotherapy
NCT04272658 ·Status: RECRUITING
-
PET/MR in Assessing Response to Neoadjuvant Radiation Therapy in the Tx of High Grade Sarcomas
NCT03076333 ·Status: COMPLETED ·Phase: NA
-
68Ga-BNU-PSMA PET/CT in Patients With Various Types of Cancer
NCT04525612 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Diagnostic Comparison of PET-magnetic Resonance and PET-CT in Patients With Oncologic Diseases
NCT02316431 ·Status: COMPLETED
-
The Diagnostic Value of PET/MRI in Head and Neck Cancer
NCT04117139 ·Status: UNKNOWN ·Phase: NA
-
A Comparison of FDG-PET Versus MRI Based Target Volume Delineation in Glioblastoma and the Role of FDG-PET/CT in the Alteration of MRI Based Target Volumes.
NCT01083719 ·Status: UNKNOWN ·Phase: PHASE2
-
PET/CT: Role in Detecting Unknown Primary Head and Neck Cancer
NCT00656760 ·Status: COMPLETED ·Phase: NA
-
Characterising Metastatic Penile Cancer Using Molecular Imaging - Hybrid MRI-PET [MRI-PET]
NCT02104063 ·Status: COMPLETED
-
18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases
NCT04752267 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Response of Brain Metastases After Gamma-Knife Radiosurgery Using Dynamic Susceptibility-weighted Contrast-enhanced Perfusion Magnetic Resonance Imaging
NCT02311556 ·Status: COMPLETED ·Phase: PHASE1
-
Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma
NCT03347617 ·Status: TERMINATED ·Phase: PHASE2
-
Imaging Correlates of Renal Cell Carcinoma Biological Features
NCT01665703 ·Status: COMPLETED ·Phase: NA
-
Assessing Cancer Treatment Response to Therapy Using 18F-FSPG PET
NCT05889312 ·Status: RECRUITING
-
Dynamic F-DOPA PET for Differential Diagnosis Between Recurrence and Radionecrosis of Brain Metastasis
NCT05762172 ·Status: COMPLETED ·Phase: NA
-
MRI-based Clinico-radiomics Predicting Lymph Node Metastasis Status of Hilar Cholangiocarcinoma
NCT05626127 ·Status: UNKNOWN
-
Comparison Between Whole Body DWI and FDG PET/CT in Patients with Simptomatic Multiple Myeloma
NCT06659276 ·Status: RECRUITING
-
Cervical Nodal Mets in Squamous Cell Carcinoma of H&N - MRI, FDG-PET, & Histopathologic Correlation
NCT00313027 ·Status: COMPLETED ·Phase: NA
-
18F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography in Oncology
NCT00207298 ·Status: COMPLETED